Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal

Could Challenge Bluebird and CRISPR/Vertex Ex Vivo Approaches

 
• By Andrew McConaghie
  
Novartis Basel
Novartis: the Basel headquartered company has pioneered CAR-Ts and gene therapies and has now invested in vivo gene editing. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip